China Universal Asset Management Co. Ltd. Sells 1,606 Shares of Regeneron Pharmaceuticals, Inc. $REGN

China Universal Asset Management Co. Ltd. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,753 shares of the biopharmaceutical company’s stock after selling 1,606 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.2% of China Universal Asset Management Co. Ltd.’s holdings, making the stock its 19th largest holding. China Universal Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $15,247,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. WPG Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $27,000. FNY Investment Advisers LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $38,000. Finally, Caitlin John LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $34,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on REGN. Oppenheimer restated an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Wells Fargo & Company lifted their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $818.13.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni, the first gene therapy to restore hearing — a clear pipeline win that validates Regeneron’s genetic‑medicine platform and de‑risks future revenue streams tied to novel products. Read More.
• Positive Sentiment: Regulatory and clinical data look strong — trial results cited high responder rates (e.g., CHORD trial outcomes reported), supporting commercial potential and positive sentiment around commercialization prospects. Read More.
• Positive Sentiment: Company secured tariff relief under the White House agreement (three years) — a near‑term margin/cost benefit that investors view favorably. Read More.
• Positive Sentiment: Analyst support/upgrades — TD Cowen raised its price target (to $960) and Cantor Fitzgerald reaffirmed “overweight,” reinforcing buy-side conviction and likely contributing to demand. Read More.
• Positive Sentiment: Dupixent label expansions (U.S./EU pediatric approvals) add incremental, low‑risk revenue upside and diversify near‑term growth drivers beyond gene therapy. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major PR/ access move that increases goodwill and access but reduces near‑term product revenue in the U.S.; it may help uptake and market positioning internationally. Read More.
• Negative Sentiment: The agreement includes offering prescriptions at “most‑favored‑nation” prices for some Americans — this could compress pricing and long‑run revenue/margins if broadly applied. Read More.
• Negative Sentiment: Sector weakness: broader health‑care stocks were lower in afternoon trading, which can cap upside even with company‑specific news. Read More.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,774 shares of company stock worth $2,942,738 over the last three months. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $766.02 on Friday. The firm has a market cap of $80.98 billion, a PE ratio of 18.43, a P/E/G ratio of 1.66 and a beta of 0.40. The business’s 50-day moving average price is $763.87 and its two-hundred day moving average price is $729.93. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company posted $12.07 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.